Disseminated Cutaneous Mucormycosis Developing in Peristomal Pyoderma Gangrenosum

Area of Science:

• Dermatology
• Mycology
• Infectious Diseases

Background:

• Peristomal pyoderma gangrenosum (PPG) is a chronic inflammatory skin condition often managed with immunosuppressants.
• Long-term glucocorticoid therapy is a common treatment for PPG, but carries risks of opportunistic infections.
• Invasive fungal infections, such as mucormycosis (MM), are rare but serious complications associated with immunosuppression.

Observation:

• A case presentation of a patient with PPG on long-term glucocorticoid therapy who developed disseminated mucormycosis.
• The patient exhibited wound dissemination of mucormycosis, indicating a severe and invasive presentation.
• This case highlights a critical adverse event associated with the management of PPG.

Findings:

• The study emphasizes the importance of skin biopsy for diagnosing PPG, especially in cases resistant to conventional therapy or with new symptoms.
• Clinical evaluation alongside diagnostic procedures is vital for accurate and timely diagnosis.
• Long-term corticosteroid use significantly increases the risk of invasive fungal infections like mucormycosis.

Implications:

• Early detection and prompt management of mucormycosis in patients with PPG are critical for improving patient outcomes.
• Healthcare providers should be vigilant for signs of invasive fungal infections in patients on long-term glucocorticoid therapy.
• This case underscores the need for careful risk-benefit assessment when prescribing long-term immunosuppression for chronic dermatological conditions.